References
Jäger U (2003) Innovative strategies in lymphoma therapy. Wien Klin Wochenschr 115 (13–14): 462–470
Gisslinger H, Kees M (2003) Therapy strategies for multiple myeloma: current status. Wien Klin Wochenschr 115 (13–14): 451–461
Sanchez-Politta S, Favet L, Kerl K, et al (2008) Bortezomib-induced skin eruption. Dermatology 216: 156–158
Gerecitano J, Goy A, Wright J, et al (2006) Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol 134 (4): 391–398
Hideshima T, Mitsiades C, Akiyama M, et al (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101: 1530–1534
Richardson PG, Sonneveld P, Schuster M, et al (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110: 3557–3560
Garcia-Navarro X, Puig L, Fernandez-Figueras MT, et al (2007) Bortezomib-associated cutaneous vasculitis. Br J Dermatol 157: 799–801
Min CK, Lee S, Kim YJ, et al (2006) Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines. Eur J Haematol 76 (3): 265–268
Kokuba H, Aurelian L, Burnett J (1999) Herpes simplex virus associated erythema multiforme (HAEM) is mechanistically distinct from drug-induced erythema multiforme: interferon-gamma is expressed in HAEM lesions and tumor necrosis factor-alpha in drug-induced erythema multiforme lesions. J Invest Dermatol 113: 808–815
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gerber, P., Bölke, E., Buhren, B. et al. Bortezomib induces erythema multiforme-like cutaneous adverse effects: report of two cases. Wien Klin Wochenschr 121, 723–724 (2009). https://doi.org/10.1007/s00508-009-1267-7
Issue Date:
DOI: https://doi.org/10.1007/s00508-009-1267-7